The FDA has approved Johnson & Johnson's Tremfya for moderately to severely active Crohn's disease, marking its fourth indication in the U.S. The approval is based on multiple Phase 3 trials involving over 1,300 patients who failed or were intolerant to previous therapies. Tremfya is the first IL-23 inhibitor offering both subcutaneous and intravenous induction options. In 2024, the drug generated $3.67 billion in sales, representing a 17% year-over-year increase.